We demonstrated that an orally administered small-molecule NLPR3 inflammasome inhibitor, NP3-361, abrogates AF inducibility in Ldlr−/− mice with hematopoietic-specific inactivation of Tet2. Here, TET2 is linked to atrial fibrillation.